DRUGS PROVIDED TO BREAST CANCER PATIENTS WITHIN THE STATE PROGRAMS OF DRUG SUPPLY

The purpose of our research was to analyze the actual practice of medicine in patients with breast cancer in various regions of the Russian Federation in the framework of state programs of drug provision (procurement of essential drugs (EDPP) and of regional benefits (RBP)).Materials and Methods. We...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Farmakoèkonomika (Moskva. Online) 2016-12, Vol.9 (3), p.8-18
Hauptverfasser: Avxentyeva, M. V., Bogin, V. I., Derkach, E. V., Omelyanovskiy, V. V., Stenina, M. B., Tarakanov, A. V., Frolov, M. Yu
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The purpose of our research was to analyze the actual practice of medicine in patients with breast cancer in various regions of the Russian Federation in the framework of state programs of drug provision (procurement of essential drugs (EDPP) and of regional benefits (RBP)).Materials and Methods. We collected data on dispensed medicines from 42 regions of the Russian Federation, which accounted for 57.58% of the total population and 58.20% of the total number of breast cancer patients who had been registered in the oncological institutions of the Russian Federation in 2013. We collected and studied data on the antineoplastic agents (L01) and hormonal antineoplastic drugs (L02) dispensed through programs of drug supply from federal and regional budgets in 2013 in the regions of the Russian Federation for patients with a diagnosis of «malignant neoplasm of the breast» (C50 International Classification of Diseases, 10th revision).Results. The number of drugs prescribed to patients with breast cancer in studied regions ranged from 3 to 39 INNs. Among the most commonly used antineoplastic agents were trastuzumab and capecitabine (both used in 92.86% of the regions), and among hormonal antineoplastic drugs were aromatase inhibitors and tamoxifen (95.24% and 100% of the regions of the Russian Federation). Consumption of drugs varied significantly between theregions.Conclusion. Our study revealed significant differences in the consumption of antineoplastic medications among outpatients with breast cancer in different regions of the Russian Federation whose care was funded by federal and regional budgets.
ISSN:2070-4909
2070-4933
DOI:10.17749/2070-4909.2016.9.3.008-018